LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) said it decided to stop enrolling patients in the phase II INDUCE-3 trial, including discontinuing treatment with feladilimab, following a recommendation by the Independent Data Monitoring Committee.
The INDUCE-3 study is investigating feladilimab in combination with pembrolizumab versus placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma.
GSK also decided to stop the INDUCE-4 phase II trial, a study investigating feladilimab versus placebo in combination with pembrolizumab and chemotherapy.
GSK said it will evaluate the data to assess the impact on the overall clinical development program for feladilimab.
Copyright RTT News/dpa-AFX
© 2021 AFX News
